Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rua BioscienceNZSE:RUA +44.83% Market Cap is NZ$14.20 Mil as of Jul. 14, 2026. The stock has 4 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Rua Bioscience ranks worse than 89.36% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rua Bioscience's share price for the quarter that ended in Dec. 2025 was NZ$0.028. Rua Bioscience's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 338.04 Mil. Therefore, Rua Bioscience's market cap for the quarter that ended in Dec. 2025 was NZ$9.47 Mil.
Rua Bioscience's quarterly market cap
increased
from Dec. 2024 (NZ$6.23 Mil) to Jun. 2025 (NZ$6.68 Mil) and
increased
from Jun. 2025 (NZ$6.68 Mil) to Dec. 2025 (NZ$9.47 Mil).
Rua Bioscience's annual market cap
declined
from Jun. 2023 (NZ$24.33 Mil) to Jun. 2024 (NZ$7.83 Mil) and
declined
from Jun. 2024 (NZ$7.83 Mil) to Jun. 2025 (NZ$6.68 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rua Bioscience's Enterprise Value for Today is NZ$13.84 Mil.
Rua Bioscience (NZSE:RUA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rua Bioscience Market Cap Related Terms
Rua Bioscience Market Cap Historical Data
* Premium members only.
The historical data trend for Rua Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:RUA vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rua Bioscience Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Rua Bioscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rua Bioscience's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rua Bioscience (NZSE:RUA) has a Market Cap of NZ$14.20 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rua Bioscience and its competitors. According to the industry distribution chart, Rua Bioscience ranks #915 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 89.4%.
Is Rua Bioscience's Market Cap too high?
Rua Bioscience's current Market Cap is NZ$14.20 Mil. Based on the distribution chart, Rua Bioscience ranks #915 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Rua Bioscience's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rua Bioscience ranks #915 out of 1024 companies for Market Cap. This places Rua Bioscience in the lower half of its industry. The industry median Market Cap is 212.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.63, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rua Bioscience and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rua Bioscience's current Market Cap is NZ$14.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rua Bioscience stock overvalued right now?
Rua Bioscience (NZSE:RUA) has a current Market Cap of NZ$14.20 Mil. The current Market Cap is NZ$14.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Rua Bioscience (NZSE:RUA), the current Market Cap is NZ$14.20 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany, and New Zealand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:RUA has been successfully added to your 
